181 related articles for article (PubMed ID: 27095306)
41. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
Carpenter RL; Ray H
Drug Saf; 2019 Feb; 42(2):263-279. PubMed ID: 30649745
[TBL] [Abstract][Full Text] [Related]
42. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
[TBL] [Abstract][Full Text] [Related]
43. Locally advanced basal cell carcinoma: Real-life data with sonidegib.
Toffoli L; Conforti C; Zelin E; Vezzoni R; Agozzino M; di Meo N; Zalaudek I
Dermatol Ther; 2022 Jun; 35(6):e15441. PubMed ID: 35279921
[TBL] [Abstract][Full Text] [Related]
44. Sonidegib: First Global Approval.
Burness CB
Drugs; 2015 Sep; 75(13):1559-66. PubMed ID: 26323341
[TBL] [Abstract][Full Text] [Related]
45. Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.
Chaudary N; Pintilie M; Hedley D; Hill RP; Milosevic M; Mackay H
Br J Cancer; 2017 Jan; 116(1):50-57. PubMed ID: 27875522
[TBL] [Abstract][Full Text] [Related]
46. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
47. Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma.
Wahid M; Jawed A; Dar SA; Mandal RK; Haque S
Onco Targets Ther; 2017; 10():515-520. PubMed ID: 28182134
[TBL] [Abstract][Full Text] [Related]
48. Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma.
Burness CB; Scott LJ
Target Oncol; 2016 Apr; 11(2):239-46. PubMed ID: 26867946
[TBL] [Abstract][Full Text] [Related]
49. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: a Retrospective Study.
Herms F; Baroudjian B; Delyon J; Laly P; Tetu P; Lebbe C; Basset-Seguin N
Acta Derm Venereol; 2022 May; 102():adv00740. PubMed ID: 35604234
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
[TBL] [Abstract][Full Text] [Related]
51. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
52. Clinical clearance of complex basal cell carcinoma in patients receiving sonidegib: A case series.
Leow LJ; Teh N
Dermatol Ther; 2022 Feb; 35(2):e15217. PubMed ID: 34816547
[TBL] [Abstract][Full Text] [Related]
53. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
54. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
55. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
[TBL] [Abstract][Full Text] [Related]
56. Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial.
Lewis K; Dummer R; Farberg AS; Guminski A; Squittieri N; Migden M
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2225-2234. PubMed ID: 34669179
[TBL] [Abstract][Full Text] [Related]
57. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Rudnick EW; Thareja S; Cherpelis B
Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
[TBL] [Abstract][Full Text] [Related]
58. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
59. Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease.
DeFilipp Z; Nazarian RM; El-Jawahri A; Li S; Brown J; Del Rio C; Smith M; Valles B; Ballen KK; McAfee SL; Rosenblatt J; Antin JH; Cutler CS; Chen YB
Blood Adv; 2017 Oct; 1(22):1919-1922. PubMed ID: 29296838
[TBL] [Abstract][Full Text] [Related]
60. Emerging drugs and combination strategies for basal cell carcinoma.
Dreier J; Dummer R; Felderer L; Nägeli M; Gobbi S; Kunstfeld R
Expert Opin Emerg Drugs; 2014 Sep; 19(3):353-65. PubMed ID: 24773312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]